Effect of montelukast on peripheral airflow obstruction in children with asthma

Spahn, Joseph D.; Covar, Ronina; Jain, Neal; Gleason, Melanie; Shimamoto, Reed; Szefler, Stanley J.; Gelfand, Erwin W.

doi:10.1016/s1081-1206(10)63548-x

Cited by 43 publications

(26 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,9,10 This new hypothesis is supported by data from studies showing that systemic inflammation is not always reduced by inhaled corticosteroids 11,12 and that systemic therapies, such as leukotriene receptor antagonists, might be more effective in reducing systemic inflammatory markers. 13,14 Furthermore, biological treatments directed at blocking IL-5 effectively decrease the signs of systemic inflammation, as measured by B-Eos values, but does not change FENO values, 15 whereas anti-IL-13 treatment reduces FENO values without decreasing B-Eos values. 16 Therefore it is reasonable to suggest that assessing both local and systemic eosinophilic inflammation in asthmatic patients would provide complementary information.…”

mentioning

confidence: 99%

Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects

Malinovschi¹,

Fonseca²,

Jacinto³

et al. 2013

Journal of Allergy and Clinical Immunology

221

158

View full text Add to dashboard Cite

Background: Fraction of exhaled nitric oxide (FENO) and blood eosinophil count (B-Eos) values, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients. Little is known about the relation of these markers to reported wheeze and asthma events in a random population sample. Objectives: We sought to determine the individual and independent values of B-Eos and FENO in relation to wheeze, asthma diagnosis, and asthma events in a cross-sectional study. 3 ) values rendered an adjusted odds ratio of 4.5 of having wheeze, 5.1 of having asthma, 5.4 for asthma attacks, and 2.9 for asthma-related ED visits compared with normal FENO (<25 ppb) and B-Eos (<300 cells/mm

show abstract

mentioning

confidence: 99%

Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects

Malinovschi¹,

Fonseca²,

Jacinto³

et al. 2013

Journal of Allergy and Clinical Immunology

221

158

View full text Add to dashboard Cite

show abstract

“…26 Spahn et al 17 have recently confirmed the effects of montelukast on peripheral airway obstruction and the concentration of eosinophilic cationic protein in children and adolescents with moderate asthma.…”

Section: Leukotrienes In Asthmamentioning

confidence: 87%

“…[13][14][15] The main effects of Cys-LT on airways can be seen in The effects of LTA are the opposite of those described for LT: LTA improve peripheral airway obstruction assessed by pulmonary volumes, air trapping, 16 airway resistance, specific conductance 17 and oscillometry. 18 They reduce the number of eosinophils in induced sputum 19 and in peripheral blood of asthmatic patients.…”

Section: What Do Treatment Guidelines Recommend?mentioning

confidence: 99%

Antileucotrienos no tratamento da asma e rinite alérgica

Ribeiro¹,

Toro²,

Baracat³

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objective: To compare leukotriene antagonists (LTA) to other groups of drugs used in asthma and allergic rhinitis treatment.Sources: MEDLINE, LILACS and Cochrane Library. Keywords: leukotrienes, antileukotrienes, asthma treatment, allergic rhinitis treatment, asthma and allergic rhinitis. An attempt was made to group the main studies and reviews about this topic Summary of the findings: LTA are more efficient than placebo and enhance the effects of inhaled corticosteroids. The association of inhaled corticosteroids with long-acting ß2 agonists is more efficient than the association of inhaled corticosteroids + LTA. Although use of LTA in acute asthma attacks and allergic rhinitis seems reasonable, more studies are needed to confirm this benefit. LTA reduce hospitalization time and the number of wheezing attacks in infants with acute viral bronchiolitis caused by respiratory syncytial virus, as well as recurrent wheezing after acute viral bronchiolitis. LTA are less efficient than intranasal corticosteroids for allergic rhinitis management. LTA are efficient in exercise-induced asthma, although they are not the first-line treatment. Conclusion:Controlled and randomized studies show that inhaled corticosteroids are the drugs of choice to treat persistent asthma and allergic rhinitis. There is not enough evidence to recommend the use of LTA as first-line drug (monotherapy) in children with asthma (level I). For children who cannot use inhaled corticosteroids, LTA may be a good alternative (level II).J Pediatr (Rio J). 2006;82(5 Suppl):S213-21: Asthma, exercise-induced asthma, rhinitis, antileukotrienes, montelukast, zafirlukast.

show abstract

“…Following treatment with montelukast (5 or 10 mg) for 8 weeks, children with mildto-moderate persistent asthma (n = 21; aged 9-18 years) had significantly lower residual volume, residual volume-total lung capacity ratio, airway resistance (Raw), better specific conductance (sGaw) and lower serum eosinophilic cationic protein (ECP) levels, as compared with placebo, suggesting an association between anti-inflammatory effects and decreased air trapping [120]. In another open study using forced impulse oscillometry (IOS) as a tool to estimate peripheral and central airway resistance, 46 children aged 6-14 years were treated with montelukast or placebo for 4 weeks.…”

Section: Diamant Mantzouranis and Bjermermentioning

confidence: 99%